BAP1 mesothelioma is a cancer that develops in the lining of the lungs, mainly in people who have been exposed to asbestos. Its predisposition to mesothelioma is genetic, and it is often inherited. It is thought that a mutated BAP1 gene increases the risk of developing the cancer. Because of its role in regulating calcium channels inside cells, it makes the cells more susceptible to the development of mesothelioma. Those with this mutation also become more resistant to chemotherapy.
However, the full spectrum of the cancer risk is unknown. In a recent study, it was shown that BAP1 gene mutations are associated with a hereditary predisposition to various cancers, including melanoma, renal cell carcinoma, and mesothelioma. Although the mutation identified is not the sole cause of BAP1-mutated mesothelioma, it is thought to explain peritoneal mesothelioma.
The recent study compared the survival rates of 23 malignant mesothelioma patients with BAP1 mutations to the survival of patients without BAP1 mutations. The study analyzed the data from the SEER Program, a program run by the National Cancer Institute to monitor cancer statistics. It revealed that the median survival for the US group was less than one year. This is a positive sign and a negative result.
The mutation has been shown to increase the risk of developing the disease. Moreover, genetic analysis has revealed that there are recurrent sites of chromosomal loss in patients with BAP1 mutations. The DNA copy number analysis has also shown that NF2 and CDKN2A are the primary driver genes. Among these, BAP1 has been implicated. Several reports on BAP1 mutations in mice show the interaction between genotype and asbestos exposure.
DNA copy number analysis has revealed that BAP1 mutation carriers are more likely to develop the disease. The early detection of the disease is associated with higher survival. Furthermore, BAP1 has been shown to increase resistance to chemotherapy. It is also found in cases of recurrent mesothelioma. This is an encouraging finding in the context of BAP1 mesothelioma.
The survival of BAP1 mesothelioma patients with this mutation is similar to that of the general population. Symptoms of the disease should be managed under the care of a medical professional. Fortunately, the prognosis for patients with BAP1 mesotheliomas is improving. These cases are not uncommon and deserve to be recognized. This is because this disease has a low genetic risk.
Despite its favorable prognosis, BAP1 is not a specific marker for mesothelioma. In other words, there is no proof that BAP1 mesothelioma causes the cancer. This genetic mutation can lead to an increased risk of developing this disease. Nonetheless, it is important to seek medical attention for mesothelioma patients who have this mutation.
Despite the lack of a genetic marker, there are a number of BAP1 mutations that can cause mesothelioma in patients. A study published in the American Journal of Cancer Research suggests that a BAP1-mutated mesothelioma has a high risk of developing the disease. While the research does not address the underlying cause of this cancer, it may point to a genetic marker.
The cancers in this study had a median age of 72 years. The majority of cases were male, with 120 (52.4%) being epithelioid and 42 (18.3%) being sar-comatoid. The BAP1 mutations were associated with shorter survival, but the study still requires further studies to prove its findings. But the results are encouraging, and it is vital to seek medical treatment as early as possible.
In addition to mesothelioma, mutations in BAP1 also cause a variety of benign tumors. In fact, some researchers have noted that the BAP1 gene causes up to 50% of all sex-cord tumors. Those with a mutation in this gene are more likely to develop mesothelioma. And there is no other genetic cause of this disease.
The genetics of the disease are unclear. However, BAP1 has been found in more than 70 percent of the mesothelioma cases and in up to 20 percent of the cancer cases in eye melanomas. It is believed that the BAP1 gene also plays a role in the occurrence of the disease in different types of cells. Those with this mutation are more likely to develop mesothelioma.